One of Wales’ leading life sciences firm, Creo Medical, has seen its share price rally after confirming that revenues for 2021 are expected to be ahead of market expectations at £25m despite the challenges of the pandemic.
The Chepstow-based and acquisitive Alternative Investment Market (AIM) listed business, which focuses on the emerging field of surgical endoscopy, said it was delivering on its ‘build, buy and partner’ strategy.
On the back of the upbeat trading statement, Creo Medical’s share price has risen around 50p to £170p in recent days adding around £91m to its market capitalisation (£311m). However, this time last year its share price was at £2.33p.